Pasithea Therapeutics Corp Dossier
Qualitative Analysis
Business overview
Pasithea Therapeutics Corp. (NASDAQ: KTTA) is a clinical-stage biotechnology company primarily focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, RASopathies, and oncology indications. The company's lead therapeutic candidate is PAS-004, a next-generation macrocyclic MEK inhibitor designed to treat a range of RASopathies, including neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas, and MAPK pathway-driven advanced solid tumors. Unlike first-generation MEK inhibitors, PAS-004 features a long half-life of approximately 70 hours, enabling once-daily or less frequent dosing. Pasithea operates as an R&D-focused entity, funding its clinical pipeline through capital markets and strategic grants.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead macrocyclic MEK inhibitor, PAS-004, through a Phase 1/1b open-label dose-escalation study in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas.
Expected impact: Aims to establish a best-in-class safety, tolerability, and efficacy profile compared to existing FDA-approved MEK inhibitors.
Expanding the therapeutic application of PAS-004 to target neurodegenerative pathologies, specifically Amyotrophic Lateral Sclerosis (ALS), where dysregulation of the MAPK pathway plays an active role.
Expected impact: Provides clinical proof-of-concept for PAS-004 in neurodegenerative diseases, addressing a massive unmet medical need.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquired to secure the global rights to CIP-137401 (now PAS-004), a next-generation macrocyclic MEK inhibitor, expanding the company's pipeline into rare RASopathies and oncology.
Financial impact: Upfront cash payment of $1.05 million, plus the issuance of 2,700,000 restricted common shares and 1,000,000 warrants.
Acquired to obtain a preclinical-stage monoclonal antibody platform (including PAS-003) targeting alpha-5 beta-1 integrin for the treatment of ALS and multiple sclerosis.
Financial impact: Paid via the issuance of 3,260,870 shares of common stock valued at $1.15 per share, plus 1,000,000 warrants.
Strategic Partnerships
Provides non-dilutive funding and scientific endorsement to evaluate the efficacy, safety, and tolerability of PAS-004 in ALS models.
Terms: Awarded a ~$1 million Hoffman ALS Clinical Trial Award grant in November 2025.